RxDoctor Payments Data

Priyanka Jindal

Family · Sharon Hill, PANPI 1457721235

Payments from drug & device makers

$5,237in general payments, 2019–2025

Across 282 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • AbbVie$833
  • Johnson & Johnson$351
  • Napo Pharmaceuticals Inc$227
  • Theratechnologies Inc.$213
  • plus $446 from 10 others

What the payments were for

  • Speaking & faculty fees$411%
  • Food & beverage$5,19699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,237 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,301
Medicare patients
16
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala87$316,563
DovatoDolutegravir Sodium/Lamivudine19$51,378
DescovyEmtricitabine/Tenofov Alafenam22$48,849
TivicayDolutegravir Sodium15$34,921
OzempicSemaglutide17$17,817
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$543
Albuterol Sulfate HfaAlbuterol Sulfate18$430
Atorvastatin Calcium69$321
Spironolactone27$284
Omega-3 Acid Ethyl Esters11$203
Nadolol13$150
Lisinopril35$140
Gabapentin21$134
Fluticasone Propionate15$124
Levothyroxine Sodium22$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,966$365,411109 claims
Viiv Healthcare CompanyDovato, Tivicay$1,201$86,29934 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$14$54311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Sharon Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →